55
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study

, , , , , , , , & show all
Pages 2595-2600 | Published online: 17 May 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Matthias Holdhoff, Nina Wagner-Johnston & Mark Roschewski. (2020) Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies. OncoTargets and Therapy 13, pages 8323-8335.
Read now

Articles from other publishers (8)

Jingjing Ma, Zhiguang Lin, Tianling Ding, Qing Li, Mengxue Zhang, Hui Kang, Patrick B. Johnston, Yan Ma & Bobin Chen. (2022) Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study. Frontiers in Oncology 12.
Crossref
Jing Xiao, Shishu Wang, Bing Xu, Lisha Yu & Yan Han. (2022) Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study. Journal of Healthcare Engineering 2022, pages 1-5.
Crossref
Shannon P. Fortin Ensign, Diamone Gathers, Julia Erin Wiedmeier & Maciej M. Mrugala. (2022) Central Nervous System Lymphoma: Novel Therapies. Current Treatment Options in Oncology 23:1, pages 117-136.
Crossref
Andrea Morales-Martinez, Fernando Lozano-Sanchez, Alberto Duran-Peña, Khe Hoang-Xuan & Caroline Houillier. (2021) Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives. Cancers 13:14, pages 3479.
Crossref
Zhenyu Pan, Guozi Yang, Jiuwei Cui, Wei Li, Yu Li, Pengxiang Gao, Tongchao Jiang, Yanan Sun, Lihua Dong, Yuanyuan Song & Gang Zhao. (2019) A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer. Frontiers in Oncology 9.
Crossref
Xinying Li, Hongxia Song, Feng Kong, Yanxia Guo, Yuan Chen, Lu Zhang, Dongfang Gao, Xiaofei Zhao & Han Zhang. (2018) Pemetrexed exerts anticancer effects by inducing G0/G1‑phase cell cycle arrest and activating the NOXA/Mcl‑1 axis in human esophageal squamous cell carcinoma cells. Oncology Letters.
Crossref
Louis Royer-Perron & Khê Hoang-Xuan. (2018) Management of primary central nervous system lymphoma. La Presse Médicale 47:11-12, pages e213-e244.
Crossref
Louis Royer-Perron, Khê Hoang-Xuan & Agusti Alentorn. (2017) Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?. Current Opinion in Neurology 30:6, pages 669-676.
Crossref